Frequency and Percentage of Cytogenetic Abnormalities
| Abnormality . | All Patients No. (%) . | Age Group (yr) . | Median Age (yr) . | Median Initial WBC-150 . | Type of AML . | |||
|---|---|---|---|---|---|---|---|---|
| 0-14 No. (%) . | 15-34 No. (%) . | 35+ No. (%) . | De Novo No. (%) . | Secondary No. (%) . | ||||
| Overall | 1,612 | 340 | 461 | 811 | 35.0 | 12.6 | 1,493 | 119 |
| No abnormality | 680 (42) | 91 (27) | 177 (38) | 412 (51) | 40.0 | 16.4 | 639 (43) | 41 (34) |
| t(15;17) | 198 (12) | 31 (9) | 87 (19) | 80 (10)-151 | 29.0-151 | 3.3-151 | 192 (13) | 6 (5) |
| +8 | 148 (9) | 46 (14) | 47 (10) | 55 (7)-151 | 27.5-151 | 7.0-151 | 137 (9) | 11 (9) |
| t(8;21) | 122 (8) | 41 (12) | 28 (6) | 53 (7)-151 | 29.5-151 | 10.7-152 | 118 (8) | 4 (4) |
| Complex | 95 (6) | 19 (6) | 29 (6) | 47 (6) | 34.0 | 7.2-151 | 84 (6) | 11 (9) |
| −7 | 61 (4) | 12 (4) | 16 (3) | 33 (4) | 37.0 | 7.0 | 48 (3) | 13 (11)-151 |
| 11q23 | 60 (4) | 26 (8) | 21 (5) | 13 (2)-151 | 17.0-151 | 17.6 | 59 (4) | 1 (1) |
| inv(16) | 57 (4) | 16 (5) | 26 (6) | 15 (2)-151 | 26.0-151 | 44.2-151 | 53 (4) | 4 (3) |
| +21 | 45 (3) | 20 (6) | 13 (3) | 12 (1)-151 | 20.0-151 | 9.7 | 39 (3) | 6 (5) |
| abn(3q) | 40 (3) | 6 (2) | 15 (3) | 19 (2) | 33.5 | 14.5 | 34 (2) | 6 (5) |
| del(7q) | 32 (2) | 7 (2) | 8 (2) | 17 (2) | 37.5 | 7.4 | 28 (2) | 4 (3) |
| del(5q) | 28 (2) | 4 (1) | 5 (1) | 19 (2) | 46.0 | 10.5 | 24 (2) | 4 (3) |
| −5 | 26 (2) | 2 (1) | 8 (2) | 16 (2) | 40.0 | 5.7 | 24 (2) | 2 (2) |
| del(9q) | 25 (2) | 12 (4) | 5 (1) | 8 (1)-151 | 19.0-152 | 13.0 | 23 (2) | 2 (2) |
| +22 | 22 (1) | 4 (1) | 9 (2) | 9 (1) | 32.0 | 11.8 | 20 (1) | 2 (2) |
| Other numerical | 219 (14) | 61 (18) | 64 (14) | 94 (12)-151 | 29.0-151 | 10.9 | 199 (13) | 20 (17) |
| Other structural | 366 (23) | 108 (32) | 86 (19) | 172 (21)-151 | 32.0-151 | 11.9 | 323 (22) | 43 (36)-151 |
| Abnormality . | All Patients No. (%) . | Age Group (yr) . | Median Age (yr) . | Median Initial WBC-150 . | Type of AML . | |||
|---|---|---|---|---|---|---|---|---|
| 0-14 No. (%) . | 15-34 No. (%) . | 35+ No. (%) . | De Novo No. (%) . | Secondary No. (%) . | ||||
| Overall | 1,612 | 340 | 461 | 811 | 35.0 | 12.6 | 1,493 | 119 |
| No abnormality | 680 (42) | 91 (27) | 177 (38) | 412 (51) | 40.0 | 16.4 | 639 (43) | 41 (34) |
| t(15;17) | 198 (12) | 31 (9) | 87 (19) | 80 (10)-151 | 29.0-151 | 3.3-151 | 192 (13) | 6 (5) |
| +8 | 148 (9) | 46 (14) | 47 (10) | 55 (7)-151 | 27.5-151 | 7.0-151 | 137 (9) | 11 (9) |
| t(8;21) | 122 (8) | 41 (12) | 28 (6) | 53 (7)-151 | 29.5-151 | 10.7-152 | 118 (8) | 4 (4) |
| Complex | 95 (6) | 19 (6) | 29 (6) | 47 (6) | 34.0 | 7.2-151 | 84 (6) | 11 (9) |
| −7 | 61 (4) | 12 (4) | 16 (3) | 33 (4) | 37.0 | 7.0 | 48 (3) | 13 (11)-151 |
| 11q23 | 60 (4) | 26 (8) | 21 (5) | 13 (2)-151 | 17.0-151 | 17.6 | 59 (4) | 1 (1) |
| inv(16) | 57 (4) | 16 (5) | 26 (6) | 15 (2)-151 | 26.0-151 | 44.2-151 | 53 (4) | 4 (3) |
| +21 | 45 (3) | 20 (6) | 13 (3) | 12 (1)-151 | 20.0-151 | 9.7 | 39 (3) | 6 (5) |
| abn(3q) | 40 (3) | 6 (2) | 15 (3) | 19 (2) | 33.5 | 14.5 | 34 (2) | 6 (5) |
| del(7q) | 32 (2) | 7 (2) | 8 (2) | 17 (2) | 37.5 | 7.4 | 28 (2) | 4 (3) |
| del(5q) | 28 (2) | 4 (1) | 5 (1) | 19 (2) | 46.0 | 10.5 | 24 (2) | 4 (3) |
| −5 | 26 (2) | 2 (1) | 8 (2) | 16 (2) | 40.0 | 5.7 | 24 (2) | 2 (2) |
| del(9q) | 25 (2) | 12 (4) | 5 (1) | 8 (1)-151 | 19.0-152 | 13.0 | 23 (2) | 2 (2) |
| +22 | 22 (1) | 4 (1) | 9 (2) | 9 (1) | 32.0 | 11.8 | 20 (1) | 2 (2) |
| Other numerical | 219 (14) | 61 (18) | 64 (14) | 94 (12)-151 | 29.0-151 | 10.9 | 199 (13) | 20 (17) |
| Other structural | 366 (23) | 108 (32) | 86 (19) | 172 (21)-151 | 32.0-151 | 11.9 | 323 (22) | 43 (36)-151 |
All patients with a specific abnormality are considered, irrespective of the presence of additional/secondary cytogenetic changes. The +21 cytogenetic group in this table and all subsequent analyses exclude 14 patients with Down's syndrome; in each of these cases, additional cytogenetic changes accompanying the +21 constitutional abnormality were used for assignment to prognostic risk group. Among 119 patients classified as secondary AML with available cytogenetics, 26 had previously been exposed to chemotherapy and/or radiotherapy, while the remainder had an antecedent hematologic disorder including 69 with documented myelodysplasia. The majority of cases with 11q23 abnormalities had balanced translocations, breakpoints on rearranged partner chromosomes were as follows: 1p32 (n = 2), 3q21 (n = 1), 4p16 (n = 1), 6q27 (n = 4), 8? (n = 1), 9p22 (n = 18), 10p12 (n = 12), 10q22 (n = 3), 17q21 (n = 5), 19p13 (n = 7), 20? (n = 1), Xq22 (n = 1), Xq24 (n = 1). In one case, a three-way rearrangement was observed (t(9;11;15)(p13;q23;q22)), while in the two remaining cases, the nature of the rearrangement was not characterized. Percents are column percents.
Ten patients did not have initial WBC recorded.
P < .001: P values are for Mantel-Haenszel test for trend in age (grouped), Wilcoxon 2-sample test in age (continuous), and for Fisher exact test in type of AML and initial WBC comparing each abnormality with normal karyotype (ie, no abnormality). Percentages may not add to 100 because of rounding.
P < .01.